NCT03267888View on ClinicalTrials.gov

Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

25

Participants

Timeline

Start Date

May 29, 2018

Primary Completion Date

September 2, 2022

Study Completion Date

September 2, 2022

Conditions
ISS Stage I Plasma Cell MyelomaISS Stage II Plasma Cell MyelomaISS Stage III Plasma Cell MyelomaRecurrent Plasma Cell MyelomaRefractory Plasma Cell Myeloma
Interventions
BIOLOGICAL

Pembrolizumab

Given 200 mg IV.

RADIATION

Radiation Therapy

Patients will receive radiotherapy (8 Gy/1 fx) to an extra-osseous site and/or any bony site containing myeloma deposit.

Trial Locations (1)

30322

Emory University/Winship Cancer Institute, Atlanta

All Listed Sponsors
collaborator

Merck Sharp & Dohme LLC

INDUSTRY

collaborator

National Cancer Institute (NCI)

NIH

collaborator

National Institutes of Health (NIH)

NIH

lead

Emory University

OTHER

NCT03267888 - Pembrolizumab and Radiation Therapy in Patients With Relapsed or Refractory Multiple Myeloma | Biotech Hunter | Biotech Hunter